FDA Approves New Nasal Spray
to Treat Depression Spravato nasal spray, also known as esketamine, can now be used for treatment-resistant depression. Esketamine is related to ketamine,
known as 'Special K,' a drug that
became a controlled substance
in 1999. Dr. Tiffany Farchione, FDA, via news release Patients who have tried at least two antidepressants are considered to have treatment-resistant depression. About one-third of U.S. adults with a major depressive disorder have treatment-resistant depression, according to Janssen Pharmaceutical Companies. Spravato should be used in conjunction with an
oral antidepressant, according to the FDA. The spray cannot be taken home and can only be administered in a certified doctor's office. Dr. Mathai Mammen Janssen, via statement